Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis
NCT05821010 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48
Last updated 2024-08-27
Summary
The goal of this clinical trial is to investigate the therapeutic potential of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and fructo-oligosaccharides with and without conditioned vegan lyophilized fecal microbiota transplantation capsules to reduce NASH in patients with fibrotic NASH. The main questions to answer are:
1. Can NASH be treated by altering the gut microbiota using LFMT capsules?
2. Can NASH be treated using a syntrophic cocktail of synbiotics and will these strains strengthen the effect of FMT?
3. What are the underlying mechanism by which the aforementioned treatments attenuate NASH?
Participants will be treated with FMT-capsules or placebo, and all participants will receive a cocktail of 3 strains of probiotics and one type of prebiotic.
Conditions
- Non Alcoholic Steatohepatitis
- Non-Alcoholic Fatty Liver Disease
- Fecal Microbiota Transplantation
- FMT
- Prebiotics
- Probiotics
- Microbiome
- Intestinal Microbiome
- Gut Microbiome
Interventions
- COMBINATION_PRODUCT
-
Lyophilized fecal microbiota transplantation capsules
Oral administration (capsule)
- COMBINATION_PRODUCT
-
Placebo capsules
Oral administration (capsule)
- DIETARY_SUPPLEMENT
-
A. soehngenii
Oral administration (capsule)
- DIETARY_SUPPLEMENT
-
Pasteurized A. muciniphila
Oral administration (capsule)
- DIETARY_SUPPLEMENT
-
B. animalis subsp. lactis
Oral administration (capsule)
- DIETARY_SUPPLEMENT
-
Fructo-oligosaccharides
Oral administration (dissolved in water)
Sponsors & Collaborators
-
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
lead OTHER
Principal Investigators
-
A.G. Holleboom, MD, PhD · Amsterdam UMC
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-17
- Primary Completion
- 2026-02-20
- Completion
- 2026-08-20
Countries
- Netherlands
Study Locations
More Related Trials
-
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study)
NCT06352697 ·Status: COMPLETED ·Phase: NA
-
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
NCT03420482 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Role of Microbiome Reprogramming on Liver Fat Accumulation
NCT03914495 ·Status: TERMINATED ·Phase: NA
-
A Pilot Study to Explore the Role of Gut Flora in Fatty Liver
NCT04160949 ·Status: WITHDRAWN
-
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
NCT00851981 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Multi Vitamin and Mineral Supplementation of Liver Enzymes and Sonography in Patient With NAFLD
NCT05897606 ·Status: COMPLETED ·Phase: PHASE1
-
Nutritional Counseling vs. Nutritional Supplements for NASH - a Randomized Prospective, Open Label Pilot Study
NCT02366052 ·Status: COMPLETED ·Phase: PHASE2
-
Histological Improvement of NASH With Prebiotic
NCT03184376 ·Status: COMPLETED ·Phase: NA
-
Supplementation of Probiotics and Fruit Fibre to Patients With Fatty Liver
NCT01423630 ·Status: TERMINATED ·Phase: NA
-
Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis
NCT02557360 ·Status: COMPLETED ·Phase: PHASE4
-
Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases
NCT02517385 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of a Probiotic on Hepatic Steatosis
NCT00099723 ·Status: TERMINATED ·Phase: PHASE1
-
Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis
NCT01922895 ·Status: TERMINATED ·Phase: NA
-
Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis
NCT02024295 ·Status: UNKNOWN ·Phase: PHASE4
-
A Feasibility Trial of OCM Supplements for the Treatment of NAFLD
NCT05720702 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Dietary Allowance of Methyl Donor Nutrients to Minimize Risks of Non-alcoholic Fatty Liver Progression
NCT05291104 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis
NCT01998620 ·Status: UNKNOWN ·Phase: PHASE4
-
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
NCT01846806 ·Status: TERMINATED ·Phase: NA
-
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients
NCT05279586 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis
NCT02464020 ·Status: COMPLETED ·Phase: PHASE1
-
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
NCT00281502 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Bacillus Coagulans on Liver and Gut Microbiota Function in NAFLD
NCT05635474 ·Status: UNKNOWN ·Phase: NA
-
Enhanced Nutritional Optimization in LVAD Trial
NCT05655910 ·Status: RECRUITING ·Phase: NA
-
Modulation of Secondary Bile Acids Through the Intestinal Microbiota After Consumption of a High-protein Diet.
NCT05906641 ·Status: COMPLETED ·Phase: NA
-
Quality of Life and Nutritional Improvements in Cirrhotic Patients
NCT01842113 ·Status: TERMINATED ·Phase: PHASE4